Keicho N, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sakurai M, Sano T, Hoshi A
Jpn J Clin Oncol. 1986 Jun;16(2):143-6. doi: 10.1093/oxfordjournals.jjco.a039130.
A phase II study of UFT (a mixture of uracil and tegafur; molar ratio of uracil to tegafur = 4) was undertaken in 21 patients with advanced non-small cell lung cancer (NSCLC). UFT was administered orally at a dose of 400 mg/m2 every day, for more than four weeks. Of 16 adequately treated patients, one (6.3%) showed a partial response. Toxic effects included minimal myelosuppression, anorexia, nausea, vomiting and epigastralgia. Gastrointestinal toxicity was well tolerated. Considering the poor response and mild toxicity, a further phase II study of higher-dose UFT is necessary for patients without prior therapy.
对21例晚期非小细胞肺癌（NSCLC）患者进行了UFT（尿嘧啶与替加氟的混合物；尿嘧啶与替加氟的摩尔比 = 4）的II期研究。UFT以每天400 mg/m²的剂量口服，持续超过四周。在16例得到充分治疗的患者中，1例（6.3%）出现部分缓解。毒性反应包括轻微的骨髓抑制、厌食、恶心、呕吐和上腹部疼痛。胃肠道毒性耐受性良好。考虑到反应不佳和毒性轻微，对于未经前期治疗的患者，有必要进一步开展高剂量UFT的II期研究。
